Retatrutide induces significant weight loss in type 2 diabetes, established CVD

Retatrutide conferred weight loss of greater than 20% for adults with obesity and type 2 diabetes, as well as those with severe obesity and established cardiovascular disease, according to topline results from two phase 3 trials. As Healio previously reported from the TRIUMPH-1 trial, adults with obesity without diabetes achieved weight loss of up to 25% at 80 weeks with once-weekly retatrutide